Unusual Machines, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Unusual Machines, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $11.20M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $5.57M | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | $0 | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | $0 | Aug 9, 2024 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.91M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $1.55M | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | $0 | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | $0 | Aug 9, 2024 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($19.19M) | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | ($31.98M) | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | ($2.38M) | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | ($1.17M) | Aug 9, 2024 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($25.15M) | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | ($16.99M) | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | ($2.38M) | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | ($1.17M) | Aug 9, 2024 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $202.6K | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $90.6K | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | $0 | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | $91.3K | Aug 9, 2024 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($21.18M) | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | ($4.00M) | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | ($1.78M) | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | ($1.19M) | Aug 9, 2024 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.06M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $0 | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | $3.2K | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | $4.6K | Aug 9, 2024 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $182.71M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $16.11M | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | $1.53M | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | $3.33M | Aug 9, 2024 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.77M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $1.29M | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | $114.5K | Mar 27, 2025 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $174.94M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $14.82M | Mar 12, 2026 |
| FY2025 | Dec 31, 2023 | $1.41M | Mar 12, 2026 |
| FY2024 | Dec 31, 2022 | $3.20M | Mar 27, 2025 |
| FY2023 | Dec 31, 2021 | $3.92M | Aug 9, 2024 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $15.60M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $7.40M | Mar 12, 2026 |
| FY2025 | Dec 31, 2023 | $0 | Mar 12, 2026 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($55.11M) | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | ($35.91M) | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | ($3.93M) | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | ($1.55M) | Aug 9, 2024 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $103.26M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $3.76M | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | $894.8K | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | $3.10M | Aug 9, 2024 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | (3) | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Aug 9, 2024 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | (3) | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Aug 9, 2024 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 37.76M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | 15.12M | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | 3.22M | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | 3.39M | Aug 9, 2024 |